23:53 , Feb 28, 2017 |  BC Innovations  |  Distillery Therapeutics

Renal

INDICATION: Diabetic nephropathy Patient sample and mouse studies suggest inhibiting VEGF-B could help treat diabetic nephropathy. In patients, VEGF-B expression was higher in kidney glomeruli tissue than in kidney tissue samples from transplant patients. In a...
07:00 , Oct 8, 2012 |  BC Week In Review  |  Clinical News

CSL preclinical data

In prediabetic mice, 2H10 significantly prevented the development of hyperglycemia compared to a control antibody (p<0.01). Additionally, 2H10 improved glucose tolerance and plasma HDL-C levels and prevented elevation of circulating triglyceride levels, LDL-C, non-esterified fatty...
08:00 , Feb 7, 2011 |  BioCentury  |  Finance

EPS Watch

EPS Watch Company 4Q10 EPS est 4Q10 EPS actual Outcome Growth from 4Q09 2/4 cls Wk chg % chg Mcap chg 2/4 Mcap Affymetrix Inc....
07:00 , Oct 11, 2010 |  BC Week In Review  |  Clinical News

Asfotase alfa: Additional Phase II data

Preliminary 6-month data from an open-label, historical cohort-controlled, North American Phase II trial in 13 patients ages 5-12 showed that thrice-weekly 2 or 3 mg/kg subcutaneous ENB-0040 produced skeletal radiographic improvement of rickets in all...
07:00 , Sep 27, 2010 |  BC Week In Review  |  Clinical News

Linagliptin: Phase III data

In a double-blind Phase III trial in 245 patients with inadequately controlled Type II diabetes, once-daily 5 mg oral linagliptin as an add-on to sulfonylurea met the primary endpoint of significantly reducing HbA1c from baseline...
07:00 , Sep 27, 2010 |  BC Week In Review  |  Clinical News

Linagliptin: Phase III data

In a double-blind Phase III trial in 227 Type II diabetics for whom metformin therapy is inappropriate, once-daily 5 mg oral linagliptin as monotherapy met the primary endpoint of significantly reducing HbA1c from baseline to...
00:12 , Sep 24, 2010 |  BC Extra  |  Top Story

U.S. restrictions, EU suspension for Avandia

FDA and the European Medicines Agency issued simultaneous decisions on Thursday based on cardiovascular safety concerns that would significantly restrict use of Avandia rosiglitazone in the U.S. and suspend the diabetes drug in the EU....
07:00 , Sep 20, 2010 |  BC Week In Review  |  Clinical News

Zactima vandetanib: Phase II data

In the double-blind Phase II ZACTHYF trial in 145 patients who failed treatment with or were unsuitable for treatment with radioiodine therapy, once-daily 300 mg oral Zactima met the primary endpoint of significantly improving PFS...
07:00 , Sep 20, 2010 |  BC Week In Review  |  Clinical News

Fidaxomicin: Additional Phase III data

Pooled data from a pair of double-blind Phase III trials in 1,164 patients showed that in patients with a recurrent episode of CDI within 3 months of entering the trials (n=128), fidaxomicin significantly reduced the...
07:00 , Sep 13, 2010 |  BC Week In Review  |  Clinical News

Lytixar: Phase IIa start

This half, Lytix will begin a double-blind, placebo-controlled, Hungarian Phase IIa trial to evaluate 1, 2 and 5% topical LTX-109 in 24 patients. Lytix Biopharma A/S, Tromso, Norway   Product: Lytixar ( LTX-109)   Business: Infectious...